Overview
The primary objective is to compare the effectiveness of the experimental Intermittent Colonic Exoperistalsis (ICE) treatment with MOWOOT, with the active control of trans-anal irrigation (TAI) as standard-of-care. The secondary objectives are to further compare the ICE treatment with MOWOOT to the TAI standard-of-care clinically and economically.
Description
The RCT will assess clinical effectiveness by means of quantitative and qualitative variables, and the cost effectiveness by means of economic outcomes.
Eligibility
Inclusion Criteria:
- Any gender 18 years or older
- Symptoms meeting the American College of Gastroenterology definition of chronic constipation: unsatisfactory defaecation characterized by infrequent stool, difficult stool passage or both for at least previous 3 months
- Bothered by their constipation
- PAC-QOL ≥1.8
- Using TAI for at least 3 months
- Able to undertake the treatment with TAI or with the device themselves or with a carer willing to do it
- Able to understand the study requirements
- Able to understand written and spoken English (due to questionnaire validity)
- Able and willing to provide written informed consent to participate
Exclusion Criteria:
Disease phenotype exclusion criteria:
- Irritable Bowel Syndrome with Diarrhoea (IBS-D) or alternating constipation and diarrhoea (IBSmix): (not due to laxative use)
- Inflammatory Bowel Disease (IBD)
Device-related exclusion criteria:
- Abdominal perimeter ≤65cm or ≥130cm
- Unable to independently use the MOWOOT or TAI technology, unless a carer is
available daily to assist
Other medical conditions, medications and contraindications:
- Previous large bowel resection
- The presence of a stoma
- External rectal prolapse
- Active anorexia or bulimia
- Active abdominal cancer
- Large inguinal or umbilical hernia
- Recent abdominal scars, abdominal wounds or skin disorders that may make abdominal massage uncomfortable
- Pregnancy or attempt to become pregnant in the next 6 months
- Use of strong opioids*
- Use of antidepressants, bladder stabilisers or any other medication inducing, or treating, constipation unless used at a stable dose for at least 4 weeks before Screening Visit (this excludes laxatives which may be used as required up to three days before the screening visit)
- Subjects already undertaking or have undertaken abdominal massage unless they underwent a previous washout period of at least 2 months
- Participation in another parallel interventional clinical trial or less than 2 months from participation in a previous interventional clinical trial
- Planned surgery for constipation if it might be within trial dates